DICOTnews December 2025
The year is drawing to a close, and we are focused on completing everything before moving on to gift wrapping and lighting candles. We are pleased to share several of these completions in this holiday edition of DICOTnews – including new encouraging discoveries about the mechanism of action and the start of preparations for Phase 2b.
I wish our shareholders and everyone following Dicot Pharma’s progress a very Merry Christmas!
Elin Trampe, CEO, Dicot Pharma
New findings on the mechanism of action
New results show that LIB-01 affects the body’s melanocortin system, which regulates sexual function and energy metabolism, among other things. These findings provide further support for LIB-01’s potential to improve erectile function even in those who do not respond to current treatments.
Patent application submitted
Based on the long-term effect demonstrated in our phase 2a study – clearly distinguishing LIB-01 from competing drugs – we have submitted a new patent application to further strengthen our IP protection.
CRO agreement ahead of phase 2b
We plan to start clinical phase 2b in the second half of 2026, and preparations are underway. We recently signed an agreement for startup activities with an international contract research organization that will manage the study, which will be conducted in the U.S. and Europe.
On stage at Aktiespararna
At the end of November, Elin Trampe presented the company and our progress at Aktiespararna’s event Stora Aktiedagarna. The interview afterward focused in particular on the positive Phase 2a results.
BIO Europe
Shortly after the report release, we presented Dicot Pharma at a company showcase organized by Oppenheimer, where the company was introduced to American investors.
Barron’s and longevity
Journalist Jack Hough at Barron’s – one of the world’s most respected financial magazines – wrote about the role erectile dysfunction plays in longevity after reading Oppenheimer’s report on the topic. He highlighted Dicot Pharma with the words: “It’s nice to see new movement in a neglected field”.
Missed Oppenheimer’s report on longevity and LIB-01? Find it here
Nomination committee appointed
Ahead of next year’s Annual General Meeting, a nomination committee has been appointed. It consists of Göran Beijer, Torsten Söderberg, and Tore Robertsson, with the latter serving as chair of the committee.
Do you want to receive press releases the moment they are published?
If you want to read our press releases as soon as they’re released, click the link below and fill in just two fields.